Literature DB >> 29736564

Change in the Binding of [11C]BU99008 to Imidazoline I2 Receptor Using Brain PET in Zucker Rats.

Kazunori Kawamura1, Tomoteru Yamasaki2, Yiding Zhang2, Hidekatsu Wakizaka3, Akiko Hatori2, Lin Xie2, Masayuki Fujinaga2, Ming-Rong Zhang2.   

Abstract

PURPOSE: The imdazoline I2 receptor (I2R) has been found in the feeding centers of the brain, such as the hypothalamus, and certain I2R ligands have been reported to stimulate food intake. Thus, it has been proposed that I2R may play a role in feeding control. [11C]BU99008 was developed as a positron emission tomography (PET) tracer for imaging of I2R. [11C]BU99008 displayed relatively high brain penetration and specific binding by brain PET studies in preclinical studies. Here, we evaluated a pathological condition caused by obesity related to I2R function by quantitative PET study using [11C]BU99008. PROCEDURES: PET scans were acquired in the Zucker (ZUC) lean and fatty rats, radioactivity and metabolites of plasma were measured, and the kinetic parameters were estimated.
RESULTS: Radioactivity levels after the injection of [11C]BU99008 in the hypothalamus of both ZUC lean and fatty rats were highly accumulated, and then gradually decreased until 60 min after the injection. The accumulated radioactivity from 30 to 60 min after the injection in the hypothalamus of the ZUC fatty rats was 1.3 times greater than that of lean rats. The volume of distribution (VT) estimated by Logan graphical analysis in the hypothalamus of the ZUC fatty rats was 1.8 times greater than that in the ZUC lean rats. In metabolite analysis, the percentages of the unchanged form in the plasma of the ZUC fatty rats at 60 min after the injection (5.0 %) was significantly lower than that of lean rats (9.1 %).
CONCLUSIONS: By PET imaging using [11C]BU99008, we demonstrated that the accumulated radioactivity and estimated VT value in the feeding center of ZUC lean rats was lower than that in fatty rats. PET studies using [11C]BU99008 may contribute to elucidate a pathological condition caused by obesity related to I2R function.

Entities:  

Keywords:  I2; Imidazoline receptor; Obesity; Positron emission tomography; Zucker rats; [11C]BU99008

Mesh:

Substances:

Year:  2019        PMID: 29736564     DOI: 10.1007/s11307-018-1206-y

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  40 in total

1.  Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.

Authors:  A Ozaita; G Olmos; M A Boronat; J M Lizcano; M Unzeta; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1997-07       Impact factor: 8.739

2.  Potential of [11C]DASB for measuring endogenous serotonin with PET: binding studies.

Authors:  Pinelopi Lundquist; Helena Wilking; A Urban Höglund; Johan Sandell; Mats Bergström; Per Hartvig; Bengt Långström
Journal:  Nucl Med Biol       Date:  2005-02       Impact factor: 2.408

Review 3.  Alpha 2-adrenoceptors and I2 sites in the mammalian central nervous system.

Authors:  N French
Journal:  Pharmacol Ther       Date:  1995       Impact factor: 12.310

4.  Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors.

Authors:  P Sánchez-Blázquez; M A Boronat; G Olmos; J A García-Sevilla; J Garzón
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  The molecular and metabolic influence of long term agmatine consumption.

Authors:  Itzhak Nissim; Oksana Horyn; Yevgeny Daikhin; Pan Chen; Changhong Li; Suzanne L Wehrli; Ilana Nissim; Marc Yudkoff
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

6.  Characterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors.

Authors:  L A Lione; D J Nutt; A L Hudson
Journal:  Eur J Pharmacol       Date:  1998-07-17       Impact factor: 4.432

7.  Synthesis, metabolite analysis, and in vivo evaluation of [(11)C]irinotecan as a novel positron emission tomography (PET) probe.

Authors:  Kazunori Kawamura; Hiroki Hashimoto; Masanao Ogawa; Joji Yui; Hidekatsu Wakizaka; Tomoteru Yamasaki; Akiko Hatori; Lin Xie; Katushi Kumata; Masayuki Fujinaga; Ming-Rong Zhang
Journal:  Nucl Med Biol       Date:  2013-04-11       Impact factor: 2.408

8.  Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines.

Authors:  P Bousquet; J Feldman; J Schwartz
Journal:  J Pharmacol Exp Ther       Date:  1984-07       Impact factor: 4.030

9.  Novel ligands for the investigation of imidazoline receptors and their binding proteins.

Authors:  A L Hudson; R J Tyacke; M D Lalies; N Davies; D P Finn; O Marti; E Robinson; S Husbands; M C W Minchin; A Kimura; D J Nutt
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

10.  Family-based association study between the monoamine oxidase A gene and obesity: implications for psychopharmacogenetic studies.

Authors:  Beatriz Camarena; Haydee Santiago; Alejandro Aguilar; Elsa Ruvinskis; Jorge González-Barranco; Humberto Nicolini
Journal:  Neuropsychobiology       Date:  2004       Impact factor: 2.328

View more
  1 in total

Review 1.  PET Imaging of Neuroinflammation in Alzheimer's Disease.

Authors:  Rong Zhou; Bin Ji; Yanyan Kong; Limei Qin; Wuwei Ren; Yihui Guan; Ruiqing Ni
Journal:  Front Immunol       Date:  2021-09-16       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.